Fetal Mortality Associated with Cholestasisof with Ursodeoxycholic

Total Page:16

File Type:pdf, Size:1020Kb

Fetal Mortality Associated with Cholestasisof with Ursodeoxycholic 580 Gut 1995; 37: 580-584 CASE REPORTS Fetal mortality associated with cholestasis of Gut: first published as 10.1136/gut.37.4.580 on 1 October 1995. Downloaded from pregnancy and the potential benefit of therapy with ursodeoxycholic acid M H Davies, R C M A da Silva, S R Jones, J B Weaver, E Elias Abstract partum, but cholestasis of pregnancy is Cholestasis ofpregnancy is associated with associated with significant fetal morbidity increased fetal morbidity and mortality and mortality.'-9 Cholestasis of pregnancy and should be treated actively. The signifi- typically develops during the third trimester of cance attached to pruritus in pregnancy is pregnancy, but occasionally presents before often minimal, but it is a cardinal symp- 20 weeks. By definition, dermatological tom of cholestasis of pregnancy, which disease should be absent, if a diagnosis is may have no other clinical features. Eight made on clinical criteria alone,9 but this is women with previous cholestasis of not necessary if biochemical evidence of pregnancy were referred to The Liver cholestasis is obtained. Most patients are not Unit within a 12 month period for advice jaundiced and many have normal standard concerning future pregnancies. Thirteen liver function tests. Serum alanine trans- pregnancies had been affected by chole- aminase (ALT) is the most sensitive of stasis of pregnancy and 12 had been the conventional liver function tests,10-12 treated expectantly with resultant peri- although serum bile acids are invariably natal morbidity or mortality in 11 (one increased.0"11 13 Symptoms vary from mild normal delivery), including; eight still- pruritus to intractable pruritus, associated births, two premature deliveries with fetal with gastrointestinal upset and icterus. distress (one died in perinatal period), and Symptoms almost invariably resolve within http://gut.bmj.com/ an emergency caesarean section for fetal one week of delivery. distress. The other pregnancy was treated Treatment of cholestasis of pregnancy varies actively and delivery was uncomplicated. widely. Despite evidence to the contrary, Subsequently, three of these cases with some obstetricians still perceive cholestasis of recurrent cholestasis of pregnancy were pregnancy as a benign condition and adopt an referred while pregnant. In each, chole- expectant policy. We report eight cases with a stasis developed with severe pruritus, gross history of cholestasis of pregnancy whose preg- on October 1, 2021 by guest. Protected copyright. increase of serum bile acids, and deranged nancies had mostly been treated conservatively. liver tests. Each was treated with the Three of these cases were pregnant at the time choleretic agent ursodeoxycholic acid, with of referral and treated with the choleretic rapid clinical improvement and resolution ursodeoxycholic acid. of deranged biochemistry. In conclusion, Birmingham Liver cholestasis of pregnancy continues to be Unit, Queen Elizabeth Hospital, Edgbaston, treated expectantly despite its association Case reports and previous obstetric Birmingham with increased morbidity and mortality histories (Table) M H Davies and evidence suggesting improved progno- R C M A da Silva E Elias sis with active treatment and the potential Case 1: 34 year old white woman of reducing the associated perinatal First pregnancy, 1986 - pruritus from 28 Department of Clinical mortality. In an uncontrolled series of weeks gestation. She was reassured. Spon- Chemistry, Queen Elizabeth Hospital, three patients with cholestasis of preg- taneous onset of labour at 37/40. Stillborn Edgbaston, nancy, ursodeoxycholic acid seemed to female. Pruritus settled within two days. Birmingham provide safe and effective therapy. Second pregnancy 1988 - pruritus from. S R Jones (Gut 1995; 37: 580-584) 27/40. Induction oflabour at 38/40, because of Birmingham previous intra-uterine death. No meconium Maternity Hospital, Keywords: cholestasis of pregnancy, fetal mortality, staining. Male baby, alive and well. Pruritus Edgbaston, prognosis, treatment, ursodeoxycholic acid. settled within Birmingham four days. J B Weaver Third pregnancy - pruritus from 26 weeks, without jaundice. Fetal movements were normal Correspondence to: Dr M H Davies, Cholestasis of pregnancy is a disease of and she was reassured. Liver functions tests Birmingham Liver Unit, unknown aetiology, which may cause severe became abnormal, with increased serum aspar- Queen Elizabeth Hospital, Edgbaston, Birmingham. and intractable pruritus. The maternal prog- tate transaminase (AST) (135). Spontaneous Accepted for publication nosis is excellent, with symptoms and bio- onset of labour at 39/40, with stillbom female. 16 February 1995 chemical derangements resolving rapidly post Pruritus settled almost immediately. Fetal mortality associated with cholestasis ofpregnancy 581 Case reports UDCA A/N Otnset Mode of Mecomiiumti Cessationi Case Pregnancy Onset RX Ictenus clinlic labour Gestationi delivety AST stainizng Olutcolme (fpruritus 1 1st 28/40 No No Yes SPONT 37/40 Vaginal 243 Yes Stillbirth 2 Days 2nd 27/40 No No Yes Induced 38/40 Vaginal 129 No Normal 4 Days 3rd 26/40 No No Yes SPONT Term Vaginal 135 Yes Stillbirth 1 Day Gut: first published as 10.1136/gut.37.4.580 on 1 October 1995. Downloaded from 4th 25/40 Yes No Yes C/s 35/40 ELEC C/s 213 No Normal 2 Days 2 1st 35/40 No No Yes SPONT 38/40 EMERG C/s N/D Yes Fetal distress 3 Days 2nd 35/40 No No Yes SPONT Term Vaginal 82 Yes Stillbirth 1 Day 3rd 28/40 Yes No Yes C/s 35/40 ELEC C/s 42 No Normal 0 Days 3 1st 28/40 No No Yes SPONT 36/40 Vaginal N/D N/K Perinatal death 7 Days 2nd None No No Yes SPONT Term Vaginal N/D No Normal N/A 3rd 32/40 No No Yes SPONT 37/40 Vaginal N/D No Normal 7 Days 4th 30/40 Yes No Yes Induced 38/40 Vaginal 205 No Normal 2 Days 4 1 st None No N/A Yes SPONT Term Vaginal N/D No Normal N/A 2nd 30/40 No No Yes SPONT 36/40 Vaginal N/D ? Fetal distress 1 Week 3rd 31/40 No No Yes SPONT Term Vaginal N/D Yes Stillbirth 2 Days 5 1 st None No N/A Yes SPONT 35/40 Vaginal N/D Yes PREM+NIL N/A* 2nd None No N/A Yes SPONT Term Vaginal N/D No Normal N/A 3rd 25/40 No No Yes SPONT 32/40 Vaginal N/D Yes Stillbirth 1 Day 6 1st 31/40 No No Yes SPONT Term Vaginal N/D Yes Stillbirth 7 Days 7 1st 28/40 No No Yes SPONT 37/40 Vaginal N/D Yes Stillbirth 7 Days 8 1st 32/40 No No Yes SPONT 37/40 Vaginal 172 Yes Stillbirth 1 Day A summary of details of all pregnancies of eight females referred subsequently to The Liver Unit. A total of 13 pregnancies were affected by cholestasis of pregnancy, resulting in two normal deliveries, two premature deliveries with fetal distress (1 perinatal death), one emergency caesarean section at 38 weeks for fetal distress, and eight stillbirths occurred. *First baby of case 5 was born premature, but with no other complications. UDCA RX=ursodeoxycholic acid therapy; N/D=liver function tests not done before delivery; A/N CLINIC=antenatal clinic; N/A=not applicable; N/K=not known; SPONT=spontancous; EMERG/ELEC C/s=emergency or elective caesarean section. Case 2: 29 year old white woman Third pregnancy - pruritus from 25 weeks First pregnancy - pruritus from 35/40. gestation, without jaundice and liver function Spontaneous onset of labour, at 38+ weeks tests were not monitored. Fetal movements gestation. Emergency caesarean section for were normal and she was reassured. Onset of fetal distress. Baby discharged alive and well. labour was spontaneous at 32 weeks, with a Pruritus settled within three days. stillborn baby delivered vaginally. Pruritus Second pregnancy - pruritus from 35/40, settled within one day. without jaundice. Fetal movements were normal, she was reassured, and the pregnancy was treated routinely. Serum AST was Case 6: a 35 year old white woman increased at 82 lU/l. Spontaneous onset of First pregnancy - pruritus from 31 weeks, labour at term, with a stillborn baby delivered without jaundice. Fetal movements normal vaginally. Pruritus settled within one day. and the pregnancy was treated routinely. Liver function tests were not monitored. http://gut.bmj.com/ Spontaneous onset of labour at term, with a Case 3: 30 year old white woman stillborn baby delivered vaginally. Pruritus First pregnancy - pruritus from 28 weeks. settled within seven days. Spontaneous labour at 36/40, with fetal dis- tress. The baby was transferred to special care baby unit (SCBU). The baby was discharged Case 7: a 28 year old white woman home, but readmitted with recurrent con- Firstpregnancy - pruritus from 28 weeks ges- on October 1, 2021 by guest. Protected copyright. vulsions and died in the perinatal period. tation, without jaundice. Liver function tests Second pregnancy - normal. were not monitored and pregnancy was treated Third pregnancy - pruritus from 32/40. routinely. Spontaneous onset of labour at Spontaneous onset of labour at 37/40, with 37/40, with a stillborn baby delivered vaginally. delivery of healthy baby. Pruritus settled within seven days. Case 4: 30 year old white woman Case 8: a 27year old white woman First pregnancy - normal. First pregnancy - pruritus from 32 weeks, Second pregnancy - pruritus from 30 weeks without jaundice. Serum AST increased at 172 gestation. Early labour, at 36/40, with fetal dis- IU/l, but fetal movements were normal and she tress. Baby discharged alive and well. was reassured. Spontaneous labour at 37 Third pregnancy - pruritus from 31 weeks weeks gestation, with a stillborn baby delivered gestation, without jaundice. The pregnancy vaginally. Relief of pruritus occurred immedi- was treated routinely. Liver function tests were ately post partum. not monitored and she was reassured. Spontaneous onset of labour at term, with stillborn baby.
Recommended publications
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Silibinin Component for the Treatment of Hepatitis
    (19) & (11) EP 2 392 326 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 07.12.2011 Bulletin 2011/49 A61K 31/357 (2006.01) A61P 1/16 (2006.01) A61P 31/12 (2006.01) (21) Application number: 11005445.9 (22) Date of filing: 14.11.2008 (84) Designated Contracting States: • Mengs, Ulrich, Dr. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51503 Rösrath (DE) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT • Pohl, Ralf-Torsten, Dr. RO SE SI SK TR 67346 Speyer (DE) • Rovati, Lucio Claudio (30) Priority: 15.11.2007 EP 07022187 20052 Monza (IT) 15.11.2007 US 988168 P • D’Amato, Massimo Maria 25.03.2008 EP 08005459 20052 Monza (IT) (62) Document number(s) of the earlier application(s) in (74) Representative: Bülle, Jan et al accordance with Art. 76 EPC: Kutzenberger & Wolff 08849759.9 / 2 219 642 Patentanwaltssozietät Theodor-Heuss-Ring 23 (71) Applicant: Madaus GmbH 50668 Köln (DE) 51067 Köln (DE) Remarks: (72) Inventors: This application was filed on 04-07-2011 as a • Ferenci, Peter, Dr. divisional application to the application mentioned 1040 Wien (AT) under INID code 62. (54) Silibinin component for the treatment of hepatitis (57) The invention relates to a silibinin component for use in the treatment of hepatitis C in a patient who does not respond to ribavirin/interferon therapy. EP 2 392 326 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 392 326 A1 Description [0001] This invention relates to the use of a silibinin component for the production of a medicament for the treatment of viral hepatitis, preferably hepatitis B or C, in particular for the reduction of the virus load.
    [Show full text]
  • Intrahepatic Cholestasis of Pregnancy: Changes in Maternal-Fetal Bile Acid Balance and Improvement by Ursodeoxycholic Acid
    ANNALS OF HEPATOLOGY Volume 1 Number 1 January-March 2002 Article: Intrahepatic cholestasis of pregnancy: Changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid Copyright © 2002: Mexican Association of Hepatology Otras secciones de Others sections in este sitio: this web site: ☞ Índice de este número ☞ Contents of this number ☞ Más revistas ☞ More journals ☞ Búsqueda ☞ Search edigraphic.com 20 Annals ofAnnals hepatology of hepatology 2002; 1(1): 1(1) January-March: 2002: 20-28 20-28 Concise Review Annals of hepatology Intrahepatic cholestasis of pregnancy: Changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid Dora Brites PhD1 Abstract in improving fetal prognosis could result in the ap- proval of UDCA for ICP treatment. Intrahepatic cholestasis of pregnancy (ICP) is a dis- ease characterized by generalized pruritus and bio- Key words: Cholestasis, Pregnancy, Ursodeoxycholic chemical cholestasis that appears typically during the acid, Bile acid. last trimester of gestation. The most predictive and accu- rate markers for diagnosis and follow-up of ICP are Introduction increased total bile acid levels (above 11,0 µmol/L), en- hanced cholic acid percentage (above 42%) and de- Cholestasis, whether resulting from hereditary or ac- creased glycine/taurine bile acid ratio (below 1.0). Al- quired liver diseases, is one of the most common manifes- though essentially benign for the mother, evidence as- tations of impaired bile flow. Intrahepatic cholestasis of sociates ICP with fetal poor prognosis resulting from pregnancy (ICP) is a condition of unknown etiology char- increased transfer of bile acids from mother to fetus, acterized by generalized pruritus and biochemical cho- who showed reduced ability to eliminate bile acids lestasis, which occurs predominantly during the last tri- across the placenta.
    [Show full text]
  • X-Ray Microscope Röntgenstrahlmikroskop Microscope À Rayons X
    (19) TZZ ___T (11) EP 2 511 844 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: G06F 21/00 (2013.01) G21K 7/00 (2006.01) 12.08.2015 Bulletin 2015/33 (21) Application number: 12164870.3 (22) Date of filing: 10.10.2007 (54) X-ray microscope Röntgenstrahlmikroskop Microscope à rayons X (84) Designated Contracting States: • Stewart, Jeffrey, J. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Los Alamos, NM 87544 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • Harris, Michael, N. SI SK TR Los Alamos, NM 87544 (US) • Burrell, Anthony, K. (30) Priority: 10.10.2006 US 850594 P Los Alamos, NM 87544 (US) (43) Date of publication of application: (74) Representative: Lorente Berges, Ana 17.10.2012 Bulletin 2012/42 A2 Estudio Legal C/ Hermosilla Nº 59, bajo izq (62) Document number(s) of the earlier application(s) in 28001 Madrid (ES) accordance with Art. 76 EPC: 07874491.9 / 2 084 519 (56) References cited: WO-A1-97/25614 US-A1- 2003 023 562 (73) Proprietor: XRpro Sciences, Inc. US-A1- 2004 128 518 US-A1- 2004 235 059 Los Alamos, NM 87544 (US) US-A1- 2005 015 596 (72) Inventors: • POTTS PHILIP J ET AL: "Atomic spectrometry • Birnbaum, Eva, R. update__X-ray fluorescence spectrometry", Los Alamos, NM 87544 (US) JOURNAL OF ANALYTICAL ATOMIC • Koppisch, Andrew, T. SPECTROMETRY, ROYAL SOCIETY OF Los Alamos, NM 87544 (US) CHEMISTRY, vol. 21, no.
    [Show full text]
  • Atc Index 2010
    ATC INDEX 2010 This is a version of the World Health Organization (WHO) ATC index and, as such, contains some substances for which data are not available in the two tables. This ATC index is sorted alphabetically according to generic/substance International Nonproprietary Name (INN). There may be some variance in the spelling of the generic name. 287 A L 04 A B 04 Adalimumab A 03 A B 16 (2-benzhydryloxyethyl) D 10 A D 03 Adapalene diethyl-methylammonium iodide D 10 A D 53 Adapalene, combinations D 01 A E 06 2-(4-chlorphenoxy)- ethanol J 05 A F 08 Adefovir dipivoxil V 03 A B 27 4-dimethylaminophenol A 16 A A 02 Ademetionine J 05 A F 06 Abacavir C 01 E B 10 Adenosine L 02 B X 01 Abarelix N 05 B A 07 Adinazolam L 04 A A 24 Abatacept V 08 A C 04 Adipiodone B 01 A C 13 Abciximab N 06 B X 17 Adrafinil L 04 A A 22 Abetimus A 01 A D 06 Adrenalone B 02 B C 01 Absorbable gelatin sponge B 02 B C 05 Adrenalone C 01 E B 13 Acadesine L 04 A B 03 Afelimomab N 07 B B 03 Acamprosate A 16 A B 03 Agalsidase alfa A 10 B F 01 Acarbose A 16 A B 04 Agalsidase beta C 07 A B 04 Acebutolol A 11 A H Agents for atopic dermatitis, excluding C 07 B B 04 Acebutolol and thiazides corticosteroids S 01 E B 08 Aceclidine N 06 A X 22 Agomelatine S 01 E B 58 Aceclidine, combinations C 01 B A 05 Ajmaline M 01 A B 16 Aceclofenac B 05 X B 02 Alanyl glutamine M 02 A A 25 Aceclofenac N 06 A B 07 Alaproclate R 03 D A 09 Acefylline piperazine P 02 C A 03 Albendazole M 01 A B 11 Acemetacin B 05 A A 01 Albumin B 01 A A 07 Acenocoumarol A 07 X A 01 Albumin tannate N 05 A A 04 Acepromazine
    [Show full text]
  • Dostupnost Léčiv Pro Trávicí Trakt a Metabolická Onemocnění: Kouzlo
    aktuálně Léky a právo ročník 27 | číslo 3/2017 Dostupnost léčiv pro trávicí trakt a metabolická onemocnění: kouzlo rovnováhy MVDr. Veronika Valdová Arete‑Zoe, LLC Souhrn Valdová V. Dostupnost léčiv pro trávicí trakt a metabolická onemocnění: kouzlo rovnováhy. Remedia 2017; 27: 250–256. V atC skupině a je možno nalézt přípravky pro léčbu v oblasti trávicího traktu a metabolických chorob. Z 34 léčiv považovaných Světovou zdravotnickou organizací za nepostradatelná jich v České republice chybí devět. některé skupiny léčiv, jako např. léčiva pro funkční poruchy trávicího systému, jsou zastoupeny jen velmi spoře. Řada nezbytných léčiv je zastoupena jen minimálním počtem registrací. nedostatek léčiv ve světě se týká především steril- ních injekčních přípravků, včetně komponent pro parenterální výživu. Dále chybějí některá důležitá léčiva uváděná ve standardních postupech napří- klad pro léčbu infekcí H. pylori a Cl. difficile. Posouzení přiměřenosti zastoupení jednotlivých indikačních podskupin je již otázkou pro klinické specialisty. anabolika a léky proti obezitě zasluhují zvláštní pozornost, a to z důvodu jejich popularity na černém trhu. V České republice jsou tato léčiva „k mání“ velmi snadno i navzdory rozsáhlé regulaci. Klíčová slova: léčiva pro trávicí trakt – nepostradatelná léčiva – dostupnost léčiv – nedostatek léčiv. Summary Valdova V. Availability of medicines used for alimentary tract and metabolic diseases treatment. Remedia 2017; 27: 250–256. the group a of the atC classification contains products for the treatment of alimentary tract and metabolic diseases. Of the 34 drugs considered essen- tial by the World Health Organization, 9 are not available in the Czech Republic. Some subgroups, such as drugs for treatment of functional disorders of BLOK GASTROENTEROLOGIE gastrointestinal tract, are represented very sparsely.
    [Show full text]
  • Australian Statistics on Medicines 2009
    Australian Statistics on Medicines 2009 Australian Statistics on Medicines 2009 Acknowledgments Prepared by Vanna Mabbott, Maxine Robinson and Quinton Brennan of the Drug Utilisation Sub-Committee Secretariat. We would like to thank the following people for their help in the access and provision of data and information used in this report: • The World Health Organization Collaborating Centre for Drug Statistics Methodology. • Jess Dalla, Jennifer Haigh and Zoe Holdenson, Special Access Programs and Special Access Programs 2, Department of Health and Ageing. • Elspeth Kay, Adverse Drug Reaction Advisory Committee, Therapeutic Goods Administration. • Jacqueline Rek, Australian Institute of Health and Welfare. Australian Statistics on Medicines 2009 Print ISBN: 978-1-74241-557-4 Online ISBN: 978-1-74241-558-1 Publications approval number: D0514 Paper-based publications © Commonwealth of Australia 2011 This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Communications Branch, Department of Health and Ageing, GPO Box 9848, Canberra ACT 2601, or via e-mail to [email protected].
    [Show full text]
  • Orphanet Journal of Rare Diseases Biomed Central
    Orphanet Journal of Rare Diseases BioMed Central Review Open Access Intrahepatic cholestasis of pregnancy Thomas Pusl1 and Ulrich Beuers*2 Address: 1Department of Medicine II, Klinikum Grosshadern, University of Munich, Munich, Germany and 2Department of Gastroenterology & Hepatology, AMC, University of Amsterdam, The Netherlands Email: Thomas Pusl - [email protected]; Ulrich Beuers* - [email protected] * Corresponding author Published: 29 May 2007 Received: 3 January 2007 Accepted: 29 May 2007 Orphanet Journal of Rare Diseases 2007, 2:26 doi:10.1186/1750-1172-2-26 This article is available from: http://www.OJRD.com/content/2/1/26 © 2007 Pusl and Beuers; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Intrahepatic cholestasis of pregnancy (ICP) is a cholestatic disorder characterized by (i) pruritus with onset in the second or third trimester of pregnancy, (ii) elevated serum aminotransferases and bile acid levels, and (iii) spontaneous relief of signs and symptoms within two to three weeks after delivery. ICP is observed in 0.4–1% of pregnancies in most areas of Central and Western Europe and North America, while in Chile and Bolivia as well as Scandinavia and the Baltic states roughly 5–15% and 1–2%, respectively, of pregnancies are associated with ICP. Genetic and hormonal factors, but also environmental factors may contribute to the pathogenesis of ICP. Intrahepatic cholestasis of pregnancy increases the risk of preterm delivery (19–60%), meconium staining of amniotic fluid (27%), fetal bradycardia (14%), fetal distress (22–41%), and fetal loss (0.4–4.1%), particularly when associated with fasting serum bile acid levels > 40 μmol/L.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0024048A1 Hemmingsen Et Al
    US 2015.0024048A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0024048A1 Hemmingsen et al. (43) Pub. Date: Jan. 22, 2015 (54) CONTROLLED RELEASE (52) U.S. Cl. PHARMACEUTICAL COMPOSITIONS FOR CPC ............. A61K9/2086 (2013.01); A61 K9/2853 PROLONGED EFFECT (2013.01); A61 K3I/573 (2013.01); A61 K 3 1/167 (2013.01); A61 K31/485 (2013.01) (71) Applicant: Egalet Ltd., London (GB) USPC ............ 424/472: 514/179; 514/630; 514/282 (72) Inventors: Pernille Hoyrup Hemmingsen, (57) ABSTRACT Bagsvaerd (DK); Anders Vagno Pedersen, Virum (DK); Daniel Layered pharmaceutical composition Suitable for oral use in Bar-Shalom, Kokkedal (DK) the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition com (21) Appl. No.: 14/446,234 prising A) a solid inner layer comprising i) an active substance, and (22) Filed: Jul. 29, 2014 ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof. Related U.S. Application Data the solid inner layer being sandwiched between two outer (63) Continuation of application No. 12/602.953, filed on layers B1) and B2), each outer layer comprising Jun. 7, 2010, now Pat. No. 8,821,928, filed as applica iii) a substantially water soluble and/or crystalline polymer or tion No. PCT/EP2008/056910 on Jun. 4, 2008. a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol in the form of one (60) Provisional application No. 60/941,848, filed on Jun. ofa) a homopolymer having a MW of at least about 100,000 4, 2007.
    [Show full text]
  • Pharmaco Sensor Jane Doe N8C9841 COVER LETTER
    Pharmaco Sensor Jane Doe N8C9841 COVER LETTER Dear Ms. Doe, Your sample for the analysis arrived on 05/02/2018 in the laboratory and was evaluated according to the highest laboratory quality standards (ISO 15189). The results were evaluated and released by two independent geneticists and molecular biologists. After obtaining the results, your personal report was compiled. We hereby transmit the results to you in the format of your choice. We would like to thank you for your trust and hope that you are satisfied with our service. We are always open for questions and suggestions, please do not hesitate to contact us. This is the only way we can continuously improve our services. We hope the analysis meets your expectations. Kind regards, Dr. Daniel Wallerstorfer BSc. Florian Schneebauer, MSc. Laboratory Director Laboratory Manager Pharmaco Sensor Personal analysis results for: Jane Doe | Date of birth: 01/02/1985 Order number: N8C9841 This report contains personal medical information that is highly confidential. Data protection must be ensured. N8C9841 Page 1 of 66 GENETICS How genes influence our health The human body consists of about 50 trillion individual cells. Most of these cells have a nucleus which contains 46 chromosomes. A chromosome consists of a very closely wound thread, the DNA "double helix." DNA, the genetic code, is Chromosome the blueprint of the human Cells body. This genetic code Body (50 trillion cells) consists of approximately 3.1 billion molecules, which are each represented by a letter. About 1% of this code makes up the genes. Each gene is an instruction for the body, usually with a single function.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,642,809 B2 Hemmingsen Et Al
    USOO9642809B2 (12) United States Patent (10) Patent No.: US 9,642,809 B2 Hemmingsen et al. (45) Date of Patent: *May 9, 2017 (54) CONTROLLED RELEASE 4.389,393 A 6, 1983 Schor et al. PHARMACEUTICAL COMPOSITIONS FOR 4.404,183 A 9, 1983 Kawata et al. 4,449,983 A 5/1984 Cortese et al. PROLONGED EFFECT 4,503,067 A 3, 1985 Wiedemann et al. 4,686,212 A 8, 1987 Ducatman et al. (71) Applicant: Egalet Ltd., London (GB) 4,769,372 A 9, 1988 Kreek 4,824,675 A 4/1989 Wong et al. (72) Inventors: Pernille Hoyrup Hemmingsen, 4,844,984 A 7, 1989 Eckenhoff et al. Bagsvaerd (DK); Anders Vagno 4,873,080 A 10, 1989 Bricklet al. 4,892,742 A 1, 1990 Shah Pedersen, Virum (DK); Daniel 4,898,733. A 2f1990 De Prince et al. Bar-Shalom, Kokkedal (DK) 5,019,396 A 5/1991 Ayer et al. 5,068,112 A 11/1991 Samejima et al. (73) Assignee: EGALET LTD., London (GB) (Continued) (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. EP O 435 T26 A2 7, 1991 EP O 908 181 4f1999 This patent is Subject to a terminal dis claimer. (Continued) (21) Appl. No.: 14/446,234 OTHER PUBLICATIONS Krogel et al (Pharmaceutical Research, 1998, vol. 15, pp. 474 (22) Filed: Jul. 29, 2014 481).* U.S. Appl. No. 13/803,132, filed Aug. 25, 2006, Purdue Pharma C.
    [Show full text]